Nuvectis Pharma (NVCT) Competitors $5.02 +0.37 (+7.96%) (As of 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NVCT vs. PROC, NGNE, VYGR, DSGN, BTMD, CTNM, SLRN, KMDA, TRVI, and CGCShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Procaps Group (PROC), Neurogene (NGNE), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), biote (BTMD), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), Trevi Therapeutics (TRVI), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Procaps Group Neurogene Voyager Therapeutics Design Therapeutics biote Contineum Therapeutics Acelyrin Kamada Trevi Therapeutics Canopy Growth Procaps Group (NASDAQ:PROC) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do insiders & institutionals have more ownership in PROC or NVCT? 96.8% of Nuvectis Pharma shares are held by institutional investors. 19.9% of Procaps Group shares are held by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor PROC or NVCT? Nuvectis Pharma received 6 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 90.00% of users gave Nuvectis Pharma an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformProcaps GroupOutperform Votes337.50% Underperform Votes562.50% Nuvectis PharmaOutperform Votes990.00% Underperform Votes110.00% Is PROC or NVCT more profitable? Procaps Group's return on equity of 0.00% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Procaps GroupN/A N/A N/A Nuvectis Pharma N/A -155.80%-104.02% Which has stronger valuation & earnings, PROC or NVCT? Procaps Group has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcaps Group$414.10M0.69$42.54M$0.524.87Nuvectis PharmaN/AN/A-$22.26M-$1.16-4.03 Does the media prefer PROC or NVCT? In the previous week, Procaps Group had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Procaps Group and 2 mentions for Nuvectis Pharma. Procaps Group's average media sentiment score of 0.00 equaled Nuvectis Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Procaps Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, PROC or NVCT? Procaps Group has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Do analysts prefer PROC or NVCT? Nuvectis Pharma has a consensus target price of $21.00, indicating a potential upside of 348.72%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNuvectis Pharma beats Procaps Group on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.42M$6.69B$5.23B$9.26BDividend YieldN/A2.98%5.12%4.28%P/E Ratio-4.0310.6587.8717.28Price / SalesN/A208.071,162.56123.53Price / CashN/A57.1543.3837.82Price / Book6.695.194.864.99Net Income-$22.26M$151.58M$120.72M$225.21M7 Day Performance-0.21%3.87%2.88%4.63%1 Month Performance-9.13%-3.42%17.99%2.54%1 Year Performance-43.55%8.06%29.13%17.21% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.458 of 5 stars$5.02+8.0%$21.00+318.3%-44.0%$96.99MN/A-4.338News CoveragePositive NewsPROCProcaps Group1.6491 of 5 stars$3.30+36.9%N/A-29.1%$372.31M$414.10M5.105,500Short Interest ↓Gap UpHigh Trading VolumeNGNENeurogene2.8445 of 5 stars$24.82+5.6%$60.83+145.1%N/A$368.70M$925,000.000.0090Short Interest ↑VYGRVoyager Therapeutics4.6451 of 5 stars$6.54+4.3%$17.00+159.9%-31.8%$357.28M$250.01M8.83100DSGNDesign Therapeutics1.0585 of 5 stars$6.28+12.1%$7.00+11.5%+137.8%$355.58MN/A-7.1840BTMDbiote2.6094 of 5 stars$6.49+1.9%$9.11+40.4%+18.3%$352.65M$193.06M24.77194Short Interest ↑CTNMContineum Therapeutics2.2526 of 5 stars$13.64-2.8%$29.25+114.4%N/A$351.61M$50M0.0031Short Interest ↓SLRNAcelyrin2.765 of 5 stars$3.35+3.7%$11.75+250.7%-55.5%$336.11MN/A-1.31135Positive NewsKMDAKamada3.9732 of 5 stars$5.83-0.7%$14.50+148.7%-0.7%$335.11M$158.38M20.96360Short Interest ↓Gap UpTRVITrevi Therapeutics2.1993 of 5 stars$4.34+4.1%$9.31+114.6%+187.8%$333.62MN/A-10.2020Short Interest ↑High Trading VolumeCGCCanopy Growth2.057 of 5 stars$3.06-1.6%$3.50+14.4%-45.3%$333.36M$220.27M-0.631,029Short Interest ↑Positive News Related Companies and Tools Related Companies PROC Alternatives NGNE Alternatives VYGR Alternatives DSGN Alternatives BTMD Alternatives CTNM Alternatives SLRN Alternatives KMDA Alternatives TRVI Alternatives CGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVCT) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
